AbbVie

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade AbbVie 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. 

CEO
Robert A. Michael
CEORobert A. Michael
Employees
57,000
Employees57,000
Headquarters
North Chicago, Illinois
HeadquartersNorth Chicago, Illinois
Founded
2011
Founded2011
Employees
57,000
Employees57,000

ABBV Key Statistics

Market cap
449.03B
Market cap449.03B
Price-Earnings ratio
124.96
Price-Earnings ratio124.96
Dividend yield
2.66%
Dividend yield2.66%
Average volume
12.37M
Average volume12.37M
High today
$253.75
High today$253.75
Low today
$252.10
Low today$252.10
Open price
$252.94
Open price$252.94
Volume
9.03K
Volume9.03K
52 Week high
$255.99
52 Week high$255.99
52 Week low
$181.75
52 Week low$181.75

Stock Snapshot

AbbVie(ABBV) stock is priced at $253.15, giving the company a market capitalization of 449.03B. It carries a P/E multiple of 124.96 and pays a dividend yield of 2.66%.

As of 2026-06-30, AbbVie(ABBV) stock has fluctuated between $252.10 and $253.75. The current price stands at $253.15, placing the stock +0.4% above today's low and -0.2% off the high.

The AbbVie(ABBV)'s current trading volume is 9.03K, compared to an average daily volume of 12.37M.

In the last year, AbbVie(ABBV) shares hit a 52-week high of $255.99 and a 52-week low of $181.75.

In the last year, AbbVie(ABBV) shares hit a 52-week high of $255.99 and a 52-week low of $181.75.

ABBV News

Reuters 2h
EXCLUSIVE: US House committee opens investigation into Merck, AbbVie China drug trials - Reuters

...

EXCLUSIVE: US House committee opens investigation into Merck, AbbVie China drug trials - Reuters
The Wall Street Journal 3h
Genmab Shares Climb After Lymphoma Therapy Hits Goal in Trial

Genmab's logo on its Copenhagen office. Genmab, AbbVie said they would discuss next steps with regulators. Joost Melis Genmab GMAB 6.87 %increase; up pointing...

Genmab Shares Climb After Lymphoma Therapy Hits Goal in Trial
Simply Wall St 13h
Is AbbVie Fully Valued After New Rinvoq And Skyrizi Approvals?

AbbVie (ABBV) has just reported a cluster of regulatory milestones, including positive European opinions for Rinvoq in severe alopecia areata and non segmental...

Is AbbVie Fully Valued After New Rinvoq And Skyrizi Approvals?

Analyst ratings

75%

of 32 ratings
Buy
75%
Hold
21.9%
Sell
3.1%

More ABBV News

TipRanks 16h
AbbVie reports ‘positive’ results from Phase 3 EPCORE DLBCL-4 trial

AbbVie (ABBV) announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of epcoritamab, a T-cell engaging bispecific antibody,...

Benzinga 19h
AbbVie Extends Reach Across Dermatology Markets With Dual Regulatory Wins

A new 55 mg pre-filled syringe (PFS) has also been approved to support weight-based dosing for patients weighing less than 40 kg, while the currently available...

AbbVie Extends Reach Across Dermatology Markets With Dual Regulatory Wins
TipRanks 20h
AbbVie’s FAST Study Wraps Up: Real-World Checkup on Ubrogepant’s Migraine Performance

Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more conf...

Nasdaq 21h
AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?

Key Points AbbVie has outperformed the market this year, but its valuation remains modest. The company recently announced the acquisition of Apogee Therapeuti...

AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?
TipRanks 1d
AbbVie announces CHMP opinion recommending approval of upadacitinib for AA

AbbVie (ABBV) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, has adopted an opinion recommending the ap...

Simply Wall St 3d
AbbVie Is Up 17.0% After EU MAVIRET Expansion And New Global Label Wins - What's Changed

In June 2026, AbbVie reported a series of regulatory wins, including expanded pediatric indications for SKYRIZI and broader HCV use for MAVIRET in Europe, along...

AbbVie Is Up 17.0% After EU MAVIRET Expansion And New Global Label Wins - What's Changed
TipRanks 3d
JPMorgan Equity Premium Income ETF Sees Inflows Amid Resilient Performance

JPMorgan Equity Premium Income ETF ( $JEPI ) has risen by 0.16% in the past week. It has experienced a 5-day net inflow of $78.3 million. This is due, in part,...

People also own

Based on the portfolios of people who own ABBV. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.